Avalo Therapeutics, Inc. (AVTX) Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Avalo Therapeutics, Inc. NASDAQ:AVTX Healthcare · Biotechnology
Mkt Cap $384.53M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics granted inducement stock options for an aggregate 101,600 shares to three new employees under Nasdaq Listing Rule 5635(c)(4).
The options were granted September 25, 2026 with a $15.47 exercise price equal to the grant-date close, vesting 25% after one year and monthly over 36 months thereafter.
This is routine hiring-related compensation disclosure with no bearing on Avalo's pipeline, including its lead anti-IL-1β candidate abdakibart now entering a Phase 3 program in hidradenitis suppurativa.
• 1mo ago AI analysis › Press Release
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
Avalo Therapeutics will present late-breaker oral and poster data on abdakibart in moderate to severe hidradenitis suppurativa at the EADV Congress 2026 in Vienna, September 30 through October 3.
The oral presentation covers Week 16 IHS4 subgroup and lesion type results from the placebo-controlled Phase 2 LOTUS trial, presented by Dr. Martina Porter of Beth Israel Deaconess Medical Center.
The release contains no new clinical data; investors will watch the October 1 presentation for detail supporting the planned Phase 3 registrational program in HS.
• 1mo ago AI analysis › Press Release
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics granted nonstatutory stock options to purchase an aggregate 78,000 shares to six new employees, with an exercise price of $19.34 per share matching the closing price on the September 2, 2026 grant date.
The awards were approved under Avalo's 2025 Inducement Award Plan pursuant to Nasdaq Listing Rule 5635(c)(4), vesting 25% at each employee's one-year anniversary with the balance vesting monthly over 36 months.
The release carries no new clinical or financial data; Avalo remains focused on advancing abdakibart into a phase 3 registrational program in hidradenitis suppurativa alongside next-generation anti-IL-1β candidate AVTX-010.
• 1mo ago AI analysis › Press Release
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics management will participate in four investor conferences in September 2026, starting with a fireside chat at the Cantor Global Healthcare Conference on September 10 at 8:00 am ET.
On September 16 the company holds 1x1 meetings at the Morgan Stanley Global Healthcare Conference and gives a presentation at the H.C. Wainwright Global Investment Conference, followed by a fireside chat at the Stifel Virtual Immunology and Inflammation Forum on September 24. Webcasts and 30-day replays will be available on Avalo's investor site.
Avalo is a clinical-stage biotech advancing its lead anti-IL-1β antibody abdakibart into a Phase 3 registrational program in hidradenitis suppurativa, with next-generation candidate AVTX-010 in development. This release is a routine calendar notice and contains no new clinical or financial information.
• 1mo ago AI analysis › Press Release ⚠ 3
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
Avalo Therapeutics ended Q2 2026 with $472.2 million in cash and investments, a position management believes will fund operations into 2029.
The company outlined a clear execution path, planning to initiate a registrational Phase 3 program for lead asset abdakibart in hidradenitis suppurativa in the first half of 2027 and submit an IND for pipeline candidate AVTX-010 in the same period.
Financial results showed a net loss of $36.4 million, or $0.83 per share, driven primarily by a $9.3 million year-over-year increase in R&D expenses tied to the abdakibart program and a recognized milestone payment.
• 2mo ago AI analysis › Press Release
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
Avalo Therapeutics CEO Dr. Garry Neil will participate in the “Honing in on Hidradenitis” panel at the virtual BTIG Biotechnology Conference on July 29, 2026.
Management is also scheduled to host one-on-one investor meetings during the event to discuss the company's pipeline.
Avalo focuses on the IL-1β pathway, with lead asset abdakibart recently reporting positive topline Phase 2 data in hidradenitis suppurativa.
• 3mo ago AI analysis › Press Release
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
Avalo Therapeutics announced that management will host one-on-one investor meetings at the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston.
The release serves as a standard investor relations update, noting the company's focus on the IL-1β pathway and its lead asset abdakibart.
No new clinical data, financial results, or strategic partnerships were disclosed in this announcement.
• 3mo ago AI analysis › Press Release
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
Avalo Therapeutics will be added to the Russell 2000 and Russell 3000 Indexes effective after the market close on June 26, 2026.
This move forces passive funds tracking the indexes to purchase shares, likely creating a near-term liquidity tailwind for the clinical-stage biotechnology company.
The company focuses on developing therapeutics targeting the IL-1β pathway, including lead asset abdakibart and next-generation candidate AVTX-010.
• 4mo ago AI analysis › Press Release
Avalo Therapeutics Appoints Ron Philip to Board of Directors
Avalo Therapeutics appointed Ron Philip to its Board of Directors, adding over 30 years of biopharmaceutical leadership experience including multiple billion-dollar exits.
Mr. Philip previously served as CEO of Orbital Therapeutics during its acquisition by Bristol Myers Squibb and as CEO of Spark Therapeutics during its acquisition by Roche.
The appointment follows Avalo's positive Phase 2 LOTUS topline results for abdakibart in hidradenitis suppurativa (HS).
• 4mo ago AI analysis › Press Release ⚠ 2
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
Avalo Therapeutics expanded its pipeline with AVTX-010, a long-acting next-generation anti-IL-1β antibody targeting immune-mediated inflammatory diseases like hidradenitis suppurativa.
The company plans to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027, leveraging positive Phase 2 data from its lead asset abdakibart.
Management highlighted productive FDA engagement that supports a streamlined path to first-in-human studies, positioning AVTX-010 to extend dosing intervals and strengthen the company's intellectual property.
• 4mo ago AI analysis › Press Release
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics granted an inducement option award for 34,000 shares to a new employee.
The award was approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and priced at $16.60 per share, equal to the closing price on the grant date.
The options vest over four years, with 25% vesting after one year and the remainder monthly thereafter, subject to continued service.
• 5mo ago AI analysis › Press Release ● Major
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Avalo Therapeutics reported positive topline results from the Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS). The trial met its primary endpoint at both doses studied, with a 42.2% and 42.9% absolute improvement in HiSCR75 response rates at Week 16.
Avalo completed a public offering of equity securities, raising gross proceeds of $431.3 million. The company's cash, cash equivalents, and short-term investments stood at $82.0 million as of March 31, 2026, not including the subsequent financing.
Research and development expenses increased by $4.9 million to $14.0 million for the three months ended March 31, 2026, driven by costs related to the Phase 2 LOTUS trial. General and administrative expenses also increased by $1.3 million to $6.9 million.
• 5mo ago AI analysis › Press Release ● Major ⚠ 2
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
Avalo Therapeutics priced a $375M public offering, selling 19.73M shares of common stock at $17.75 per share and 1.4M pre-funded warrants.
Underwriters have a 30-day option to purchase an additional 3.17M shares.
Proceeds will fund the Phase 3 topline data release for lead asset abdakibart (AVTX-009) and support general corporate purposes.
• 5mo ago AI analysis › Press Release
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Avalo Therapeutics announced a proposed public offering of common stock and pre-funded warrants to fund its ongoing operations.
Net proceeds are intended to advance the Phase 3 development of its lead asset abdakibart and for general corporate purposes.
Leerink Partners, TD Cowen, and BofA Securities are acting as joint book-running managers, with an underwriter option for an additional 15% of shares.
• 5mo ago AI analysis › Press Release ● Major
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
Avalo Therapeutics reported positive topline results from the Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa, successfully meeting the primary HiSCR75 endpoint at both doses studied.
The 150 mg and 300 mg doses demonstrated response rates of 42.2% and 42.9% respectively, compared to a 25.6% placebo rate, with statistically significant improvements observed in key secondary endpoints as well.
Based on these de-risking results, Avalo plans to advance abdakibart into a registrational Phase 3 program.
• 5mo ago AI analysis › Press Release
Avalo Therapeutics Purchases Optional Milestone Buyout
Avalo Therapeutics entered into a Milestone Buyout Option Agreement to modify the terms of its prior acquisition of AlmataBio, effectively replacing a $15 million contingent milestone liability.
Under the new terms, Avalo paid $2.25 million for a 90-day option to pay an additional $5.125 million in cash, stock, or a combination upon Phase 3 initiation, significantly reducing potential future cash outflows.
The company remains focused on its lead asset abdakibart (AVTX-009), an IL-1β based treatment currently in a Phase 2 trial for hidradenitis suppurativa.
• 6mo ago AI analysis › 
